REGENERON PHARMACEUTICALS, INC.·4

May 29, 4:01 PM ET

BROWN MICHAEL S 4

4 · REGENERON PHARMACEUTICALS, INC. · Filed May 29, 2024

Insider Transaction Report

Form 4
Period: 2024-05-28
Transactions
  • Exercise/Conversion

    Non-Qualified Stock Option (right to buy)

    2024-05-281,1721,535 total
    Exercise: $625.60Exp: 2032-01-03Common Stock (1,172 underlying)
  • Exercise/Conversion

    Common Stock

    2024-05-28$625.60/sh+1,172$733,2032,554 total
  • Sale

    Common Stock

    2024-05-28$974.86/sh1,172$1,142,5361,382 total
Holdings
  • Common Stock

    (indirect: By Trust)
    6,162
  • Common Stock

    (indirect: by SLAT)
    5,000
Footnotes (3)
  • [F1]Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 26, 2024.
  • [F2]These shares are held in a trust for the benefit of the reporting person's immediate family members. The reporting person's spouse is trustee of the trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
  • [F3]On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that had passed from the date of grant became exercisable, and the remainder became exercisable on the first anniversary of the date of grant.

Documents

2 files